Labcorp (LH)
(Delayed Data from NYSE)
$198.41 USD
+0.41 (0.21%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $198.39 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
LH 198.41 +0.41(0.21%)
Will LH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LH
Why Labcorp (LH) is a Top Value Stock for the Long-Term
Why Labcorp (LH) is a Top Value Stock for the Long-Term
LH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Labcorp (LH) to Assess Preeclampsia Risk With New Test
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for LH
Laboratory Holdings Executives Present at Growth Stock Conference
Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio
Labcorp announces new strategic service offerings
Sell ideas in Staples and Health Care - Oppenheimer
Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting